PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

NCT06429696 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: PD-L1 inhibitor combined with apatinib

Sponsor

Nanfang Hospital, Southern Medical University